Congratulations to Dr. Melita Tate and the clinical research team at Grassroots Healthcare for recently setting a new benchmark by screening the first patient studywide. This Phase 3 migraine trial evaluates an oral therapeutic designed for acute treatment of migraine attacks in adults. This first patient screened milestone represents an important step forward in research for a painful and often debilitating condition.

The Burden of Migraine

Migraines are a genetically influenced neurological disorder that can be characterized by episodes of moderate-to-severe headaches that can last hours to days. The condition is widespread, affecting millions of people worldwide. Migraine attacks are often accompanied by nausea and sensitivity to light and sound, significantly impacting quality of life. Even with available therapies, many patients experience recurring episodes or find current treatments inadequate, highlighting the need for new therapeutic options.

Therapeutic Expertise

This acute migraine trial milestone is the latest in a long history of enrollment success for Dr. Tate, who has been an embedded Principal Investigator within the DelRicht network since 2019. Bringing over 19 years of medical experience and a highly engaged patient base, Dr. Tate is widely recognized across the clinical research industry for her operational precision and patient engagement.

Having led more than 45 clinical trials as a PI, her therapeutic expertise spans complex general medicine indications including but not limited to: migraine, obesity, type 2 diabetes, hypertension, warts, pain, and fibromyalgia. Her leadership, combined with the dedication of the research staff, makes the site a vital contributor to advancing clinical research in Oklahoma and beyond.

The achievement of the first patient screened within the same day as activation reflects the team’s preparation, responsiveness, and deep commitment to patients. This accomplishment required not only efficient study start-up processes but also the ability to engage and support participants quickly, ensuring they felt confident in contributing to the trial. Tyler Hastings, Managing Partner at DelRicht Research, added:

“Acute migraine trials require an operational model that can capture patient data at the precise moment an episode occurs. By achieving the first patient screened studywide, Dr. Tate’s team has proven that our network can rapidly engage this highly specific patient population without compromising protocol compliance.” –

Tyler Hastings, Managing Partner at DelRicht Research

Moving Medicine Forward

By participating in this Phase 3 trial, patients have the opportunity to contribute to research that could shape the future standard of care for migraines. For sponsors and CROs, rapid activation and immediate patient screening demonstrate the value of partnering with experienced, high-performing sites that prioritize both operational timelines and patient care.

DelRicht Research is proud to partner with investigators like Dr. Tate, who brings expertise, innovation, and a shared mission of improving patient care through clinical research. Together, we connect patients with future therapies by expanding clinical trial access.

Partnering With DelRicht Research

DelRicht Research is a nationwide, multidisciplinary network of 33 community-based sites dedicated to increasing patient participation in clinical trials. By embedding full-service research infrastructure and experienced site management teams within independent physician practices, DelRicht delivers high-quality, scalable clinical research while maintaining a community-centered approach to trial access. Through centralized study start-up to localized recruitment strategy, DelRicht optimizes study recruitment timelines and data collection for global sponsors and CROs looking to develop therapeutics in general medicine indications like acute migraine.

Learn more about our current studies in migraine research.